Look Ma! No Bong! Afrezza Inhaled Insulin Device is a Cool Gadget
UPDATE (1/5/2016): Sanofi terminated its license agreement related to the development and commercialisation of MannKind's inhaled insulin therapy Afrezza, MannKind said today (here). MannKind...
Patient Centricity, Transparency, & Pharma’s Reputation: Getting Beyond Lip Service
This article discusses real world examples of patient-centricity in pharmaceutical marketing and the need for more transparency in how pharmaceutical companies partner with patients online.
The Next FDA Commissioner Will Be… Industry Pundits Think It’s a Shoe-In. Do You?
In a new survey, Pharma Marketing News asks your opinion about who should be the next FDA commissioner.
The survey has been seeded with the candidates mentioned in this article. You can choose one of these or enter your own choice.
The Consumer Brief Summary: FDA’s New Thinking Regarding Risk Communication
New FDA guidelines jettison the 'traditional approach' to fulfilling the brief summary requirement and replaces it with what the FDA calls the 'Consumer Brief Summary.' This article summarizes the new guidelines and reviews the need for additional guidelines that specifically address the fair balance section of DTC print ads.
Pharma Marketing News Vol. 14, No. 2: February 2015
Welcome to Vol. 14, Issue No. 2 (FEBRUARY 2015) of Pharma Marketing News. The FDA is a hot topic in this issue. Specifically, it's new thinking on presenting risk information in direct-to-consumer print ads. Are the new guidelines relevant for online advertising?
When It Comes to Social Media, Pharma Tells Patients: “Do As We Say, Not...
Weeding out unsavory, "offensive," or spammy comments is a fact of social media life that has to be dealt with. In general, pharmaceutical companies...
Transparency is Good in Theory, But Not in Practice
I attended SMi's Social Media in the Pharmaceutical Industry conference this week and, as usual whenever I attend these conferences in the UK, I...
FDA Says It Will Not Regulate Low-Risk Mobile Health Apps as Medical Devices
"CDRH does not intend to examine low risk general wellness products to determine whether they are devices within the meaning of the FD&C...
“Innovative” Pharma Marketing Is Not Viral
Several recent articles and blog posts have claimed there is a lack of "Innovation" among pharma marketers who are afraid to "rock the boat."
World...
LAP-BAND’s Social Media Campaign Definitely Violates FDA Guidelines
I heard that a number of participants at the 33rd Annual J.P. Morgan Healthcare Conference in San Francisco were "baffled" by LAP-BAND's social media...
